Pilot Study - Safety and Efficacy of Dalbavancin in Early Outpatient Treatment of Erysipelas and Limited Cellulitis

Acute bacterial skin and skin structure infection (ABSSSI) Erysipelas

Percentage of patients who are dischargeable 48-72 hours after the Dalbavancin infusion due to sufficient infection control., Incidence of adverse events during therapy (up to day 28)., Incidence of Dalbavancin-associated adverse events.

Proportion of patients who do not require readmission between hospital discharge and follow-up evaluation associated with infection., Percentage of inpatient patients who can be discharged on day 8 due to sufficient infection control, Proportion of patients who require readmission on day 8 due to insufficient infection control., Duration of hospitalization., Infection-associated rehospitalization rate within 4 weeks after discharge., Percentage of patients without recurrent BHWI within 4 weeks after discharge., Proportion of patients without recurrent BHWI within a 4-6 week follow-up period., Percentage of patients requiring a change in antibiotic therapy (regimen change) within 14 days of starting treatment., Proportion of patients with adequate antibiotic coverage by Dalbavancin according to the antibiogram.

No related papers found yet.

Papers published before 2002-11-01 may not appear yet. Historical indexing is in progress.